{"filing":{"accession_number":"0001104659-26-077546","cik":"0001661059","ticker":"NXTC","company_name":"NextCure, Inc.","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"nxtc-20260618x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1661059/000110465926077546/nxtc-20260618x8k.htm"},"events":[{"id":13723,"run_id":12190,"accession_number":"0001104659-26-077546","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"NextCure held its Annual Meeting of Stockholders on June 18, 2026, with shareholders voting on four proposals: election of two Class I directors (Anne Borgman and John G. Houston), ratification of Ernst \u0026 Young LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2019 Omnibus Incentive Plan. The filing discloses detailed voting results for all four proposals.","company_name":"NextCure, Inc.","ticker":"NXTC","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":10944,"accession_number":"0001104659-26-077546","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment and restatement of the 2019 Omnibus Incentive Plan, which increases authorized shares by 80,000 and modifies the evergreen provision. This is a compensatory arrangement disclosure under Item 5.02(e), as it involves material changes to the equity incentive plan structure that governs executive and employee compensation. The shareholder vote approval and plan amendment are material to investors assessing the company's capital allocation and dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T12:03:02.684639+00:00","company_name":"","ticker":null,"filing_date":""},{"id":10945,"accession_number":"0001104659-26-077546","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This is a clear disclosure of shareholder voting results from NextCure's June 18, 2026 Annual Meeting of Stockholders. The filing presents tabulated results for four proposals: election of two Class I directors (Anne Borgman and John G. Houston), ratification of Ernst \u0026 Young LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2019 Omnibus Incentive Plan. Item 5.07 is the designated Item for shareholder vote results, and the prose explicitly states \"The results of the voting at the Annual Meeting are shown below,\" followed by detailed vote tallies. This is material to investors as it reflects stockholder decisions on board composition, auditor selection, executive pay, and equity plan authorization.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T12:03:02.684639+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10944,"accession_number":"0001104659-26-077546","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an amendment and restatement of the 2019 Omnibus Incentive Plan, which increases authorized shares by 80,000 and modifies the evergreen provision. This is a compensatory arrangement disclosure under Item 5.02(e), as it involves material changes to the equity incentive plan structure that governs executive and employee compensation. The shareholder vote approval and plan amendment are material to investors assessing the company's capital allocation and dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T12:03:02.684639+00:00","company_name":"NextCure, Inc.","ticker":"NXTC","filing_date":"2026-06-25"},{"id":10945,"accession_number":"0001104659-26-077546","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This is a clear disclosure of shareholder voting results from NextCure's June 18, 2026 Annual Meeting of Stockholders. The filing presents tabulated results for four proposals: election of two Class I directors (Anne Borgman and John G. Houston), ratification of Ernst \u0026 Young LLP as independent auditor, advisory approval of named executive officer compensation, and approval of an amendment to the 2019 Omnibus Incentive Plan. Item 5.07 is the designated Item for shareholder vote results, and the prose explicitly states \"The results of the voting at the Annual Meeting are shown below,\" followed by detailed vote tallies. This is material to investors as it reflects stockholder decisions on board composition, auditor selection, executive pay, and equity plan authorization.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T12:03:02.684639+00:00","company_name":"NextCure, Inc.","ticker":"NXTC","filing_date":"2026-06-25"}]}